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Objectives: Expression of the cell-cell adhesion molecules E-cad-
herin and α-, β-, and γ-catenin seems closely related to tumor inva-
siveness. The relationship between the expression and
clinicopathologic characteristics in surgically resected non–small
cell lung cancers of 3 cm or less in size was studied. The relation-
ship to patient survival was analyzed.
Methods: A total of 115 patients with surgically resected lung can-
cers of 3 cm or less in size were enrolled in this study. Expression
of E-cadherin and α-, β-, and γ-catenin was immunohistochemi-
cally measured. The χ2 test was used to correlate this expression
with clinicopathologic parameters. Their influence on patient sur-
vival was evaluated with the Cox proportional hazards model.
Results: There was a positive correlation between E-cadherin and
catenin expression in lung cancers. In general, E-cadherin and
catenin expression were greater in tumors that were either bronchi-
oloalveolar carcinomas or adenocarcinomas, well differentiated, early stage,
peripheral, and without vascular or pleural invasion. By using multicovariate analy-
sis of patient survival, only early-stage and peripheral tumors were significantly
favorable prognostic factors. Further analysis of the group of patients with early-
stage disease showed that higher α-, β-, or γ-catenin expression was a favorable
prognostic indicator.
Conclusion: Expression of α-, β-, or γ-catenin can be used as a prognostic indicator
in patients with surgically resected stage I non–small cell lung cancers of 3 cm or
less in size.
Lung cancer is the most common cause of cancer death in Taiwan.Although a significant proportion of non–small cell lung cancers(NSCLCs) are detected when the tumor is less than 3 cm in size, theresults of surgical treatment in this category of patients are not uni-formly favorable.1,2 Small-sized lung cancers can present at an earlyor late stage of tumor development, and survival depends on the bio-
logic characteristics of the tumor. Various investigators have shown that pathologic
staging with the TNM system is the most significant prognostic indicator. Other
histopathologic features, such as histologic type, degree of differentiation, vascular
invasion, and mitotic index, can also help to predict the patient’s outcome.
Nevertheless, even at the same stage and with similar pathologic characteristics,
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surgically treated, 3-cm or smaller NSCLCs can have a vari-
able prognosis. Recent advances in tumor cell biology will
help to shed light on the associated mechanics of tumor
invasion and metastasis.3,4
Tumor invasion and metastasis are complex processes
involving an interaction between the biologic characteristics of
the tumor cells and the competence of host defenses. Alteration
of cell-cell adhesion molecules may play a role in tumor-cell
detachment in the early stages of tumor invasion and metasta-
sis.5-8 E-cadherin is a subclass of the cadherin family that plays
a major role in the maintenance of intercellular junctions in
epithelial tissues. This function also depends on an interaction
between the cytoplasmic domain of the cadherin molecule
with the cytoskeleton through E-cadherin–associated cytoplas-
mic proteins know as α-, β-, and γ-catenin, which form an
E-cadherin-catenin complex.9-11 It has been reported that
underexpression of E-cadherin; α-, β-, and γ-catenin; or both
may be closely related to dedifferentiation and invasiveness in
many types of human epithelial cancers.12-15 In the present
study we investigated the clinicopathologic significance of
E-cadherin and α-, β-, and γ-catenin expression in terms of
their association with patient prognosis after surgical treatment
of NSCLCs of 3 cm or less in size.
Materials and Methods
During the period from January 1990 to December 1997, 115
patients who had small-sized (≤3 cm) NSCLCs and had undergone
complete surgical resection at the National Taiwan University
Hospital were consecutively enrolled in the study. All of the
resected tumor specimens and dissected lymph nodes were forma-
lin fixed, sectioned, and stained with hematoxylin and eosin for
microscopic examination. Histologic diagnoses and pathologic
features were obtained, including histologic type, degree of differ-
entiation, regional lymph node metastasis, microscopic tumor
emboli, and the presence of direct invasion to the pleura or chest
wall. Pathologic staging was performed according to the
International Union Against Cancer (1997),16 which is based on
tumor size, location and involvement, and the presence of lymph
node metastases or distant metastases.
The study group included 66 male and 49 female patients, and
the mean age of the group was 59.2 years (range, 32-81 years).
Clinical data for each of these patients were collected and included
sex, age, smoking history, symptoms, signs, and location of the
tumor. Smoker was defined as more than 1 pack-year of smoking
history. The survival status of the patients was followed at regular
outpatient clinics or by communication. The follow-up period
ranged from 30 to 110 months. The clinical and pathologic data
were analyzed with reference to the expression of E-cadherin and
α-, β-, and γ-catenin in each tumor.
Immunohistochemistry
For immunohistochemical study of E-cadherin and α-, β-, and γ-
catenin expression in the tumor tissue, 4-µm-thick sections from
each formalin-fixed, paraffin-embedded tissue block were treated
with 0.3% hydrogen peroxide in methanol and heated in a
microwave oven for 20 minutes to block endogenous peroxidase.
The tissue sections were then incubated with normal nonimmune
goat serum. After excessive goat serum had been blotted, the slides
were incubated separately with 4 specific mouse monoclonal anti-
bodies, including anti-E-cadherin (Takara Shuzo Co Ltd, Kyoto,
Japan), anti-α-catenin, anti-β-catenin, and anti-γ-catenin
(Transduction Laboratories, San Diego, Calif) for 1 hour at room
temperature. After being washed with phosphate-buffered solution
(PBS) 3 times, the sections were incubated with bionylated goat
anti-mouse antibody for 20 minutes at room temperature. The sec-
tions were again washed 3 times with PBS and then incubated with
peroxidase-conjugated streptavidin for 15 minutes at room tem-
perature. After a third triple washing with PBS, the sections were
stained with 0.05% (3′,3)-diamino-benzidine tetrachloride freshly
prepared in 0.05 mol/L Tris-HCl (pH 7.6) containing 0.01%
hydrogen peroxide. Finally, the sections were counterstained with
methylene green and mounted.
Figure 1. Normal bronchial epithelium used as a positive internal
control. (Original magnification ×66.)
Figure 2. Immunohistochemical study of a moderately differenti-
ated adenocarcinoma shows diffuse cell membrane staining for
β-catenin in the lung cancer. (Original magnification ×66.)
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By use of normal bronchial epithelium adjacent to the tumor as
an internal positive control (Figure 1), the expression of E-cadherin
and α-, β-, and γ-catenin for each tumor was assessed. The expres-
sion of these 4 markers was considered as positive if the intensity
of stained tumor cells was comparable with that of normal epithe-
lial cells. For each marker, 500 tumor cells per 10 high-power fields
were counted. After observation by 2 pathologists, the percentage
of positive-stained tumor cells in each tumor was recorded. The
lung tumors studied were divided into 2 groups. A lung tumor was
categorized as strongly positive if 50% or more of the tumor cells
were stained (Figure 2) or categorized as weakly positive or nega-
tive if less than 50% of the tumor cells were stained.
Statistical Analysis
Correlation of various clinical or pathologic parameters with the
expression of E-cadherin and α-, β-, and γ-catenin was performed
with the χ2 test. Survival curves were estimated by using the
Kaplan-Meier method, and differences in survival were evaluated
with the general Wilcoxon test. The multicovariate relationships
were analyzed with the Cox proportional hazards general linear
model.
Results
In the present study the rate of high E-cadherin expression
(≥50%) in NSCLCs of less than 3 cm was 56.3%. The rates
TABLE 1. E-cadherin and α-, β-, and γ-catenin expression in NSCLCs of 3 cm or less in size with relation to clinical
parameters
Proportion of Proportion of Proportion of Proportion of
Parameter E-cadherin <50% (%) α-catenin <50% (%) β-catenin <50% (%) γ-catenin <50% (%)
Age (y)
<60 13/37 (35.1) 9/37 (24.3) 5/36 (13.9) 10/35 (18.6)
≥60 36/75 (48.0) 21/77 (27.3) 13/78 (16.7) 21/74 (28.4)
Sex
Male 34/63 (54.0)* 23/66 (34.8)* 13/65 (20.0) 18/62 (29.0)
Female 15/49 (30.6)* 7/48 (14.6)* 5/49 (10.2) 13/47 (27.7)
Status of smoking
Smoker 28/43 (65.1)* 19/45 (42.2)* 12/45 (26.7)* 12/42 (28.6)
Nonsmoker 18/62 (29.0)* 10/62 (16.1)* 6/63 (9.5)* 17/60 (28.3)
Tumor location
Central 26/31 (83.9)* 15/32 (46.9)* 10/32 (31.2)* 12/31 (38.7)
Peripheral 23/81 (28.4)* 15/82 (18.3)* 8/82 (9.8)* 19/78 (24.4)
*P < .05.
TABLE 2. E-cadherin and α-, β-, and γ-catenin expression in NSCLCs of 3 cm or less in size with relation to pathologic char-
acteristics
Proportion of Proportion of Proportion of Proportion of
Pathologic characteristics E-cadherin <50% (%) α-catenin <50% (%) β-catenin <50% (%) γ-catenin <50% (%)
Histologic type
Squamous cell 16/22 (72.7)* 13/24 (54.2)* 8/23 (34.8)* 8/21 (38.1)
Adenocarcinoma 29/54 (53.7)* 13/54 (24.1)* 6/55 (10.9)* 17/54 (31.5)
Bronchioloalveolar 3/34 (8.8)* 3/34 (8.8)* 3/34 (8.8)* 5/32 (15.6)
Grade of differentiation
Well 6/41 (14.6)* 6/41 (14.6) 4/41 (9.8) 9/39 (23.1)
Moderate 30/56 (53.6)* 17/58 (29.3) 11/58 (19.0) 17/56 (30.4)
Poor 12/13 (92.3)* 6/13 (46.2) 2/13 (15.4) 4/12 (33.3)
Tumor stage
Stage I 24/73 (32.9)* 17/75 (22.7) 10/75 (13.3) 18/70 (25.7)
Stage II 2/10 (20.0)* 2/10 (20.0) 0/10 (0) 1/10 (10.0)
Stage III 23/29 (79.3)* 11/29 (37.9) 8/29 (27.6) 12/29 (41.4)
Vascular invasion or emboli
+ 9/12 (75.0)* 5/13 (38.5) 3/13 (23.1) 3/12 (25.0)
– 39/99 (39.4)* 24/100 (24.0) 14/100 (14.0) 27/96 (28.1)
Pleural invasion
+ 10/13 (76.9)* 5/12 (41.7) 5/13 (38.5)* 6/13 (46.2)
– 38/98 (38.8)* 34/101 (23.8) 12/100 (12.0)* 24/95 (25.3)
*P < .05.
Lee et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 3   505
TX
ET
CS
P
G
TS
CH
D
G
TS
ED
IT
O
RI
A
L
of high α-, β-, and γ-catenin expression (≥50%) were
73.7%, 84.2%, and 71.6%, respectively. There was a posi-
tive correlation between E-cadherin expression and α-, β-,
and γ-catenin expression. Expression among the 3 catenins
was also significantly correlated.
The relationship between various clinical parameters in
these patients with the extent of E-cadherin and α-, β-, or γ-
catenin expression is shown in Table 1. Higher E-cadherin
and α-catenin expression was noted in female patients, non-
smokers, and patients with peripheral tumors. Higher β-
catenin expression was also noted in nonsmokers and in
patients with peripheral tumors. With reference to the
pathologic characteristics of the tumor, higher E-cadherin
expression was noted in tumors with histologic characteris-
tics, including bronchioloalveolar carcinoma (BAC), adeno-
carcinoma, higher grades of differentiation, early tumor
stage, absence of vascular invasion, or absence of pleural
invasion. Higher α-catenin and β-catenin expression was
also noted in tumors with histologic characteristics of BAC
or adenocarcinoma. Higher β-catenin expression was noted
in tumors without pleural invasion (Table 2).
The influence of various clinicopathologic parameters
on patient survival was analyzed, including the expression
of E-cadherin and α-, β-, or γ-catenin. By using single-vari-
ate analysis of survival, significantly better prognostic indi-
cators included BAC, stage I and stage II tumors, peripheral
tumors, tumors without pleural invasion, and increased lev-
els of E-cadherin and α-, β-, or γ-catenin expression. By
using multiple covariate analysis, only early-stage and
peripheral tumors remained as independent prognostic fac-
tors indicating significantly better survival. These patients
were then divided according to their tumor stage, and a total
Figure 3. Survival curves in patients with stage I, surgically
resected, small-sized NSCLCs with higher (≥50%) or lower (<50%)
E-cadherin (E-cad) expression (P = .26).
Figure 4. Survival curves in patients with stage I, surgically
resected, small-sized NSCLC with higher (≥50%) or lower (<50%)
α-catenin (α-cat) expression (P < .05).
Figure 5. Survival curves in patients with stage I, surgically
resected, small-sized NSCLC with higher (≥50%) or lower (<50%)
β-catenin (β-cat) expression (P < .05).
Figure 6. Survival curves in patients with stage I, surgically
resected, small-sized NSCLC with higher (≥50%) or lower (<50%)
γ-catenin (γ-cat) expression (P < .05).
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of 75 patients had stage I tumors. An analysis of the effect
of various clinicopathologic factors on patient survival was
performed for these patients with stage I disease. By using
single-variate analysis, female sex and increased expression
of E-cadherin and α-, β-, or γ-catenin were found to be sig-
nificantly better prognostic indicators (Figure 3). By using
multiple covariate analysis, increased expression of α-, β-,
and γ-catenin remained as an independent, favorable prog-
nostic indicator (Figures 4-6). No significant prognostic
factors could be found for the other stages of lung cancer,
which may be due to the limited sample size. Further inves-
tigation of prognostic indicators for the other stages of lung
cancer is required.
Discussion
Small-sized lung tumors are frequently encountered by tho-
racic surgeons. The associated prognosis after surgical
intervention is quite variable and usually dependent on the
tumor pathology, namely the tumor’s grade and stage.1,2 In
the present study multivariate analysis showed that in addi-
tion to tumor stage, the location of the tumor was also a sig-
nificant prognostic indicator.
It has been recognized that reduced expression of the
cell-to-cell adhesion molecule E-cadherin is closely related
to the dedifferentiation and invasiveness of a tumor.17 The
association of catenins with E-cadherin is an essential
requirement for the correct function and maintenance of
cell-cell adhesions within a tissue.9-11 In the present study
the percentages of reduced expression of E-cadherin and α-,
β-, and γ-catenin were 43.7%, 26.4%, 15.8%, and 28.4%,
respectively. These results were comparable with those of
other studies of NSCLC with the same criteria for assess-
ment.14,18 A positive correlation between reductions in E-
cadherin and α-, β-, and γ-catenin were also noted in this
study, which was similar to the results of studies of gastric
carcinoma, hepatocellular carcinoma, and breast can-
cer.12,19,20 The mechanism of simultaneous reduction of E-
cadherin and catenins is unclear. A mutual influence of
underexpression of this group of molecules may occur at
the gene, transcription, or protein level.
A positive correlation between reduced E-cadherin, α-
catenin, or β-catenin expression and patients who smoked
or had central tumors was identified in this study. This phe-
nomenon may be partly explained by the fact that most of
the tumors in smokers or centrally located tumors were of
the non-BAC type. BAC exhibited significantly higher
expression of E-cadherin and catenins when compared with
non-BAC tumors, which was similar to the results of the
study by Hidaka and colleagues.18 In this study reduced
expression of E-cadherin correlated significantly with de-
differentiation, advanced stage, and vascular and pleural
invasion. With catenins, there was also a tendency toward
reduced expression in tumors that were poorly differenti-
ated, of advanced stage, or invasive, but this tendency was
not statistically significant. These results suggest that when
compared with catenins, a reduction in E-cadherin expres-
sion was more prominent when defects of cell-cell adhesion
were present in NSCLC. The invasiveness of the tumor may
largely be influenced by these cell-cell adhesion molecules,
particularly E-cadherin.
The association between E-cadherin and catenin expres-
sion on patient survival has been reported for various types
of human cancers. Reduced expression of α-catenin influ-
ences patient survival in prostate, ovarian, colorectal, and
bladder cancer.15,21-23 Reduced β-catenin expression is pre-
dictive of a poorer prognosis in gastric cancer.24 In NSCLC
the prognostic significance of E-cadherin and catenin
expression has remained unclear to date. In our previous
study of surgically treated NSCLC, E-cadherin expression
was shown to have no prognostic value as a whole, and the
preliminary data showed that E-cadherin was a significant
prognostic factor between large (>3 cm) and small (≤3 cm)
lung tumors by means of univariate analysis.16 In the pres-
ent study neither E-cadherin nor catenin expression in
small-sized NSCLCs were shown to have prognostic signif-
icance after multicovariate survival analysis. Nevertheless,
if only patients with early-stage disease are included in the
analysis, reduced expression of α-, β-, and γ-catenins
became a significant prognostic factor indicative of a poorer
outcome. These results are not dissimilar to those of previ-
ous studies of prostate and ovarian cancer.15,21 These results
suggest that loss of α-, β-, or γ-catenin expression in early-
stage NSCLC indicates a higher potential for malignancy.
In conclusion, the results of the present study demon-
strated a close correlation between reduced E-cadherin
expression and tumor dedifferentiation, advanced tumor
stage, and tumor invasion in NSCLCs of 3 cm or less in
size. Reduced expression of α-, β-, or γ-catenin indicates a
poorer prognosis in stage I NSCLCs of 3 cm or less in size.
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